Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
Rhea-AI Summary
Verrica Pharmaceuticals (Nasdaq: VRCA) will report fourth quarter and full year 2025 financial results and provide a corporate update on March 11, 2026.
The company will host a conference call and live webcast at 8:30 a.m. ET; dial-in details, conference ID VERRICA, and a 90-day webcast replay are available on the company website.
Positive
- None.
Negative
- None.
News Market Reaction – VRCA
On the day this news was published, VRCA declined 2.44%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
VRCA gained 4.1% while key biotech peers showed mixed moves: several names like PSTV, CALC, OTLK and RADX were up, and GRCE was down. Only OTLK appeared in the momentum scanner, suggesting today’s move in VRCA looks more stock-specific around its upcoming earnings date.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Conference participation | Neutral | -3.1% | Participation in TD Cowen healthcare conference with webcast access for investors. |
| Feb 12 | Executive appointment | Positive | -2.3% | Appointment of seasoned Chief Commercial Officer to expand YCANTH commercialization. |
| Feb 09 | Product launch | Positive | +0.0% | Launch of YCANTH in Japan by partner Torii for molluscum contagiosum. |
| Jan 07 | Clinical milestone | Positive | +0.9% | First patient dosed in global Phase 3 program for common warts. |
| Nov 24 | Financing / capital raise | Positive | +12.1% | $50M private placement to repay debt and extend expected cash runway. |
Recent fundamentally positive updates (clinical progress, financing, commercial steps) have not always produced consistent upside, with mixed alignment between news tone and next-day price moves.
Over the last several months, Verrica announced a $50 million private placement to retire debt and extend cash runway into mid-2027, a key capital milestone that saw the stock rise over 12%. It then reported initiation of a global Phase 3 program for YCANTH, supported by Torii funding, plus the Japan launch of YCANTH and a new Chief Commercial Officer. Conference participation and commercial build-out have followed. Today’s earnings-date announcement fits into this sequence of commercialization and financing execution.
Regulatory & Risk Context
An effective S-3 shelf dated Dec 15, 2025 registers up to 14,756,230 shares of common stock for resale by existing stockholders. Verrica does not receive proceeds from these resales but would receive cash upon exercise of the underlying pre-funded and common warrants at stated exercise prices. The filing also references prior auditor commentary about substantial doubt regarding the company’s ability to continue as a going concern.
Market Pulse Summary
This announcement schedules Verrica’s fourth quarter and full year 2025 results for March 11, 2026, giving investors a clear near-term catalyst. Shares trade below the 200-day MA of $6.03 and roughly 45.73% under the 52-week high, framing expectations into the event. Recent history includes a $50 million financing to extend runway and progress in YCANTH development and commercialization. Upcoming metrics on cash, commercialization, and pipeline spend will be key to watch.
AI-generated analysis. Not financial advice.
WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2025, and provide a corporate update.
Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register.
A live audio webcast of the call can also be accessed by visiting the investor relations section of the Company’s website, www.verrica.com, or by clicking here. A replay of the webcast will be archived on Verrica’s website for 90 days following the event.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
FAQ
When will Verrica (VRCA) report Q4 and full year 2025 results?
How can investors join the Verrica (VRCA) earnings call on March 11, 2026?
What time and conference ID does Verrica (VRCA) use for the March 11, 2026 call?
Will Verrica (VRCA) provide a replay of the March 11, 2026 webcast?
Where can I find the Verrica (VRCA) webcast and investor materials for March 11, 2026?
